WHWK
Whitehawk Therapeutics Inc
1W: -8.2%
1M: +17.7%
3M: +56.1%
YTD: +47.1%
1Y: +77.7%
3Y: -55.2%
5Y: -85.4%
$3.59
+0.00 (+0.00%)
After Hours: $3.46 (-0.13, -3.62%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$169.4M
52W Range1.39-4.48
Volume158,165
Avg Volume146,974
Beta0.64
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODavid J. Lennon
Employees40
SectorHealthcare
IndustryBiotechnology
IPO Date2017-08-01
Websiteir.whitehawktx.com
17383 Sunset Blvd, Suite A250
Pacific Palisades, CA 90272
US
Pacific Palisades, CA 90272
US
551 321 2234
About Whitehawk Therapeutics Inc
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Latest News
Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK
2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC
Whitehawk Therapeutics GAAP EPS of -$0.34
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BALL BRYAN | S-Sale | 1,834 | $3.31 | 2026-03-02 |
| Lennon David James | S-Sale | 5,100 | $3.31 | 2026-03-02 |
| Giacobello Scott M. | S-Sale | 2,594 | $3.31 | 2026-03-02 |
| BALL BRYAN | M-Exempt | 5,000 | — | 2026-03-01 |
| BALL BRYAN | M-Exempt | 5,000 | — | 2026-03-01 |